

Curriculum vitae

Heike Irmgard Grabsch

January 2016

Personal Details

Name: Heike Irmgard GRABSCH
MBA*, MB ChB*, MD*, PhD⁺, FRCPath[§]
* Degrees obtained in Hamburg and Köln, Germany
⁺ University of Leeds, UK
[§] Royal College of Pathologists, UK

Current position: Professor in Gastrointestinal Pathology
Leeds Institute of Cancer and Pathology
University of Leeds, UK
and
Department of Pathology
Maastricht University Medical Centre+
P. Debyelaan 25
6229 HX Maastircht
NL

Email: H.I.Grabsch@leeds.ac.uk
H.Grabsch@maastrichtuniversity.nl

Higher Degrees

June 2011	2nd Higher Research Degree: PhD, University of Leeds, UK
January 2006	FRCPath by examination, Royal College of Pathologists, London
July 2003	Postgraduate Certificate in Health and Research (with merits) University of Leeds, UK
October 1996	1st Higher Research Degree: MD (magna cum laude) Department of Anatomy, University of Köln, Germany
December 1990	State Exam in Medicine (German equivalent of MB ChB) University of Hamburg and Köln, Germany
September 1983	Graduated in Business Management (German equivalent of MBA) Business Academy, Hamburg, Germany

Postgraduate Career

July 2014 - to present

Professor in GI Pathology, Maastricht University Medical Centre, Maastricht, NL

July 2014 - to present

Professor in GI Pathology (honorary appointment) University of Leeds, UK

August 2006 - June 2014

Senior Clinical Lecturer in Gastrointestinal Pathology

Honorary Consultant Histopathologist

University of Leeds and Leeds Teaching Hospitals NHS Trust

August 2002-July 2006

Lecturer in Gastrointestinal Pathology/Honorary SpR in Histopathology,

University of Leeds and Leeds Teaching Hospitals NHS Trust

December 2000 to July 2002

Specialist Registrar in Histopathology

Leeds Teaching Hospitals NHS Trust, Leeds, UK

May 1998 to November 2000

Specialist Registrar in Histopathology (German equivalent)

Institute of Pathology, University of Düsseldorf, Düsseldorf, Germany

October 1996 to April 1998

SHO/Specialist Registrar in Histopathology (German equivalent)

Institute of Pathology, Klinikum Leverkusen,

Teaching Hospital University of Köln, Germany

May 1996 to September 1996

Post Doc Research Fellow

Zentrum für Molekulare Medizin, University of Köln, Germany

February 1993 to April 1996

Assistant Lecturer and Demonstrator in Anatomy

Department of Anatomy, University of Köln, Germany

July 1991 to January 1993

House Officer in Paediatrics (German equivalent)

Paediatric Clinic, Köln, Germany

* * * * *

October 1983 to 31 October 1984

Business Administrator/Manager (German equivalent)

Deutsche Shell AG, Hamburg, Germany

Grant funding (2002 - 2014)

January 2013	Yorkshire Cancer Research project grant. “Amplification frequency and prognostic value of key receptor tyrosine kinase signalling genes in oesophago-gastric cancer - working towards a biomarker driven, multi-targeted agents trial to improve clinical outcome” PI: Dr H Grabsch, £182,801 for 3 years
December 2012	Cancer Research UK CTAAC Additional funding for the OE05 tissue collection. £ 28,143.57.
August 2012	Leeds Teaching Hospitals Charitable Foundation. Pilot project grant. Developing the toolkit for the OPTIMUM (Oesophagogastric cancer: assessment of Preoperative sTaging ImproveMents Using MRI) study. £ 23,671
May 2012	Cancer Research UK CTAAC Additional funding for the ST03 tissue collection. £ 61,262.98 for 2 years.
March 2012	Studies into Japanese gastro-oesophageal cancer (£2500) Sasakawa Foundation
July 2010	Japanese Collaborative Grant (£5000) Pathological Society of Great Britain and Ireland
July 2009	Educational Fellowship Grant (£5000) British Division International Academy of Pathology Dedicated for a 3 weeks visit at the National Cancer Institute in Tokyo and the Tokyo Metropolitan Geriatric Medical Center, Japan
December 2007	Cancer Research UK TRICC Project Grant Title: Biological sample collection from patients entering the UK NCRI ST03 clinical trial.PI: H Grabsch; £ 157,890 for 4 years.
December 2007	Cancer Research UK TRICC Project Grant Title: Biological sample collection from patients entering the UKCRN OE05 clinical trial.PI: H Grabsch; £ 173,663 for 4 years.
July 2007	Cancer Research UK TRICC Project Grant Title: Prognostic and predictive factors in a randomised controlled clinical trial of pre-operative chemotherapy in resectable oesophageal cancer (OE02). PI: H Grabsch; £ 290,696 for 3 years.

Membership of Learned Societies

International Gastric Cancer Association
International Society for Diseases of the Esophagus
Pathological Society of Great Britain and Ireland
International Academy of Pathology, British Division
Association of Clinical Pathologists, UK
British Association of Cancer Research
European Association of Cancer Research
British Society of Gastroenterologists

Involvement in National and International GI Cancer Clinical Trials

Principal investigator of translational studies in OE02, OE05, ST03
Reference histopathologist in ongoing trials:
OE05, ST03, ASPECT, BRIDE, NeoSCOPE, INNOVATION
Member of the SCOPE1 Trial Management Group (trial closed)
Member of the REAL3 Trial Steering Committee (trial closed)
Co-investigator and member of the ST03 Trial Management Group (trial closed)
Co-investigator and member of the OE05 Trial Management Group (trial closed)
Co-investigator and member of the NeoScope Trial Management Group (trial closed)
Member of the ROMIO Trial Steering Committee
Co-investigator and member of the GO-2 Trial Management Group
Member of the EORTC INNOVATION Trial Steering Committee

Papers published in peer reviewed journals

1. Rohwer N, Bindel F, Grimm C, Lin SJ, Wappler J, Klinger B, Blüthgen N, Du Bois I, Schmeck B, Lehrach H, de Graauw M, Goncalves E, Saez-Rodriguez J, Tan P, **Grabsch HI**, Prigione A, Kempa S, Cramer T. Annexin A1 sustains tumor metabolism and cellular proliferation upon stable loss of HIF1A. *Oncotarget*. 2015 Dec 29. doi: 10.18632/oncotarget.6793. [Epub ahead of print]
2. Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, Ylstra B, van Grieken N, Rha SY, Chung HC, Lee JS, Cheong JH, Noh SH, Aoyama T, Miyagi Y, Tsuburaya A, Yoshikawa T, Ajani JA, Boussioutas A, Yeoh KG, Yong WP, So J, Lee J, Kang WK, Kim S, Kameda Y, Arai T, zur Hausen A, Speed TP, **Grabsch HI**, Tan P. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. *Gut*. 2015 Nov;64(11):1721-31.
3. Matula K, Collie-Duguid E, Murray G, Parikh K, **Grabsch H**, Tan P, Lalwani S, Garau R, Ong Y, Bain G, Smith AD, Urquhart G, Bielawski J, Finnegan M, Petty R. Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phosphate lyase determines chemotherapy resistance in gastroesophageal cancer. *BMC Cancer*. 2015 Oct 22;15:762.
4. Feilchenfeldt J, Varga Z, Siano M, **Grabsch HI**, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Khanfir K, Diebold J, Jochum W, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Hofer S. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). *Br J Cancer*. 2015 Sep 1;113(5):716-21.
5. Hale MD, Gotoda T, Hayden JD, **Grabsch HI**. Endoscopic biopsies from gastrointestinal carcinomas and their suitability for molecular analysis: a review of the literature and recommendations for clinical practice and research. *Histopathology*. 2015 Aug;67(2):147-57.
6. Tominaga N, Gotoda T, Hara M, Hale MD, Tsuchiya T, Matsubayashi J, Kono S, Kusano C, Itoi T, Fujimoto K, Moriyasu F, **Grabsch HI**. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. *Gastric Cancer*. 2015 May 19. [Epub ahead of print]

7. Zhang S, Tan IB, Sapari NS, **Grabsch HI**, Okines A, Smyth EC, Aoyama T, Hewitt LC, Inam I, Bottomley D, Nankivell M, Stenning SP, Cunningham D, Wotherspoon A, Tsuburaya A, Yoshikawa T, Soong R, Tan P. Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues. *J Mol Diagn*. 2015 May;17(3):242-50.
8. Yamada T, Yoshikawa T, Taguri M, Hayashi T, Aoyama T, Sue-Ling HM, Bonam K, Hayden JD, **Grabsch HI**. The survival difference between gastric cancer patients from the UK and Japan remains after weighted propensity score analysis considering all background factors. *Gastric Cancer*. 2015 Mar 12. [Epub ahead ofprint] PubMed PMID: 25761964.
9. Mukherjee S, Hurt CN, Gwynne S, Bateman A, Gollins S, Radhakrishna G, Hawkins M, Canham J, Lewis W, **Grabsch HI**, Sharma RA, Wade W, Maggs R, Tranter B, Roberts A, Sebag-Montefiore D, Maughan T, Griffiths G, Crosby T. NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. *BMC Cancer*. 2015 Feb 12;15:48.
10. Wright AI, **Grabsch HI**, Treanor DE. RandomSpot: A web-based tool for systematic random sampling of virtual slides. *J Pathol Inform*. 2015 Feb 24;6:8.
11. Bain GH, Collie-Duguid E, Murray GI, Gilbert FJ, Denison A, McKiddie F, Ahearn T, Fleming I, Leeds J, Phull P, Park K, Nanthakumaran S, **Grabsch HI**, Tan P, Welch A, Schweiger L, Dahle-Smith A, Urquhart G, Finegan M, Petty RD. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas. *Br J Cancer*. 2014 Mar 18;110(6):1525-1534
12. Su X, Zhan P, Gavine PR, Morgan S, Womack C, Ni X, Shen D, Bang YJ, Im SA, Ho Kim W, Jung EJ, **Grabsch HI**, Kilgour E. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. *Br J Cancer*. 2014 Feb 18;110(4):967-75.
13. Labots M, Buffart TE, Haan JC, van Grieken NC, Tijssen M, van de Velde CJ, **Grabsch HI**, Ylstra B, Carvalho B, Fijneman RJ, Verheul HM, Meijer GA. High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection. *Cell Oncol (Dordr)*. 2014 Feb;37(1):41-52
14. Voorham QJ, Janssen J, Tijssen M, Snellenberg S, Mongera S, van Grieken NC, **Grabsch H**, Kliment M, Rembacken BJ, Mulder CJ, van Engeland M, Meijer GA, Steenbergen RD, Carvalho B. Promoter methylation of Wnt-antagonists in polypoid and nonpolypoid colorectal adenomas. *BMC Cancer*. 2013 Dec 19;13:603.
15. **Grabsch HI**, Tan P. Gastric cancer pathology and underlying molecular mechanisms. *Dig Surg*. 2013;30(2):150-8
16. Ilyas M, **Grabsch H**, Ellis IO, Womack C, Brown R, Berney D, Fennell D, Salto-Tellez M, Jenkins M, Landberg G, Byers R, Treanor D, Harrison D, Green AR, Ball G, Hamilton P. Guidelines and considerations for conducting experiments using tissue microarrays. *Histopathology*. 2013 May;62(6):827-39
17. van Grieken NC, Aoyama T, Chambers PA, Bottomley D, Ward LC, Inam I, Buffart TE, Das K, Lim T, Pang B, Zhang SL, Tan IB, Carvalho B, Heideman DA, Miyagi Y, Kameda Y, Arai T, Meijer GA, Tsuburaya A, Tan P, Yoshikawa T, **Grabsch HI**. KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study. *Br J Cancer*. 2013 Apr 16;108(7):1495-501
18. Hale MD, Hayden JD, **Grabsch HI**. Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response. *Cell Oncol (Dordr)*. 2013 Apr;36(2):95-112
19. Gwynne S, Falk S, Gollins S, Wills L, Bateman A, Cummins S, **Grabsch H**, Hawkins MA, Maggs R, Mukherjee S, Radhakrishna G, Roy R, Sharma RA, Spezi E, Crosby T. Oesophageal Chemoradiotherapy in the UK-Current Practice and Future Directions. *Clin Oncol (R Coll Radiol)*. 2013 Jun;25(6):368-77
20. Hayashi T, Yoshikawa T, Bonam K, Sue-Ling HM, Taguri M, Morita S, Tsuburaya A, Hayden JD, **Grabsch HI**. The superiority of the seventh edition of the TNM classification depends on the overall survival of the patient cohort: Comparative analysis of the sixth and seventh TNM editions in patients with gastric cancer from Japan and the United Kingdom. *Cancer*. 2013 Apr 1;119(7):1330-7
21. Salih T, Jose P, Mehta SP, Mirza A, Udall G, Pritchard SA, Hayden JD, **Grabsch HI**. Prognostic significance of cancer within 1 mm of the circumferential resection margin in oesophageal cancer patients following neo-adjuvant chemotherapy. *Eur J Cardiothorac Surg*. 2013 Mar;43(3):562-7.

22. Izon AS, Jose P, Hayden JD, Grabsch HI. Significant variation of resected meso-esophageal tissue volume in two-stage subtotal esophagectomy specimens: A retrospective morphometric study. *Ann Surg Oncol*. 2013 Mar;20(3):788-97.
23. Mehta SP, Jose P, Mirza A, Pritchard SA, Hayden JD, Grabsch HI. Comparison of the prognostic value of the 6th and 7th editions of the Union for International Cancer Control TNM staging system in patients with lower esophageal cancer undergoing neoadjuvant chemotherapy followed by surgery. *Dis Esophagus*. 2013 Feb;26(2):182-8.
24. Sanders S, Grabsch H, Harrison R, Bateman A, Going J, Goldin R, Mapstone N, Novelli M, Walker M, Jankowski J. Comparing virtual with conventional microscopy for the consensus diagnosis of Barrett's neoplasia in the AspECT Barrett's chemoprevention trial. *Histopathology*. 2012 Nov;61(5):795-800.
25. Abdulkareem FB, Sanni LA, Richman SD, Chambers P, Hemmings G, Grabsch H, Quirke P, Elesha SO, Banjo AF, Atoyebi OA, Adesanya AA, Onyekwere CA, Ojukwu J, Anomneze EE, Rotimi O. KRAS and BRAF mutations in Nigerian colorectal cancers. *West Afr J Med*. 2012 Jul-Aug;31(3):198-203.
26. Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, Sanders S, Gay L, Pech O, Longcroft-Wheaton G, Romero Y, Inadomi J, Tack J, Corley DA, Manner H, Green S, Al Dulaimi D, Ali H, Allum B, Anderson M, Curtis H, Falk G, Fennerty MB, Fullarton G, Krishnadath K, Meltzer SJ, Armstrong D, Ganz R, Cengia G, Going JJ, Goldblum J, Gordon C, Grabsch H, Haigh C, Hongo M, Johnston D, Forbes-Young R, Kay E, Kaye P, Lerut T, Lovat LB, Lundell L, Mairs P, Shimoda T, Spechler S, Sontag S, Malfertheiner P, Murray I, Nanji M, Poller D, Ragunath K, Regula J, Cestari R, Shepherd N, Singh R, Stein HJ, Talley NJ, Galimiche JP, Tham TC, Watson P, Yerian L, Ruge M, Rice TW, Hart J, Gittens S, Hewin D, Hochberger J, Kahrilas P, Preston S, Sampliner R, Sharma P, Stuart R, Wang K, Waxman I, Abley C, Loft D, Penman I, Shaheen NJ, Chak A, Davies G, Dunn L, Falck-Ytter Y, Decaestecker J, Bhandari P, Ell C, Griffin SM, Attwood S, Barr H, Allen J, Ferguson MK, Moayyedi P, Jankowski JA. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. *Gastroenterology* 2012 Aug;143(2):336-46.
27. The Esophageal Adenocarcinoma Genetics Consortium; The Wellcome Trust Case Control Consortium 2, Su Z, Gay LJ, Strange A, Palles C, Band G, Whiteman DC, Lescai F, Langford C, Nanji M, Edkins S, van der Winkel A, Levine D, Sasieni P, Bellenguez C, Howarth K, Freeman C, Trudgill N, Tucker AT, Pirinen M, Peppelenbosch MP, van der Laan LJ, Kuipers EJ, Drenth JP, Peters WH, Reynolds JV, Kelleher DP, McManus R, Grabsch H, Prenen H, Bisschops R, Krishnadath K, Siersema PD, van Baal JW, Middleton M, Petty R, Gillies R, Burch N, Bhandari P, Paterson S, Edwards C, Penman I, Vaidya K, Ang Y, Murray I, Patel P, Ye W, Mullins P, Wu AH, Bird NC, Dallal H, Shaheen NJ, Murray LJ, Koss K, Bernstein L, Romero Y, Hardie LJ, Zhang R, Winter H, Corley DA, Panter S, Risch HA, Reid BJ, Sargeant I, Gammon MD, Smart H, Dhar A, McMurtry H, Ali H, Liu G, Casson AG, Chow WH, Rutter M, Tawil A, Morris D, Nwokolo C, Isaacs P, Rodgers C, Ragunath K, Macdonald C, Haigh C, Monk D, Davies G, Wajed S, Johnston D, Gibbons M, Cullen S, Church N, Langley R, Griffin M, Alderson D, Deloukas P, Hunt SE, Gray E, Dronov S, Potter SC, Tashakkori-Ghanbaria A, Anderson M, Brooks C, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Duncanson A, Markus HS, Mathew CG, Palmer CN, Plomin R, Rautanen A, Sawcer SJ, Trembath RC, Viswanathan AC, Wood N, Trynka G, Wijmenga C, Cazier JB, Atherfold P, Nicholson AM, Gellatly NL, Glancy D, Cooper SC, Cunningham D, Lind T, Hapeshi J, Ferry D, Rathbone B, Brown J, Love S, Attwood S, Macgregor S, Watson P, Sanders S, Ek W, Harrison RF, Moayyedi P, de Caestecker J, Barr H, Stupka E, Vaughan TL, Peltonen L, Spencer CC, Tomlinson I, Donnelly P, Jankowski JA. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. *Nat Genet* 2012 Sep 9;44(10):1131-1136
28. Voorham QJ, Carvalho B, Spiertz AJ, Claes B, Mongera S, van Grieken NC, Grabsch H, Kliment M, Rembacken B, van de Wiel MA, Quirke P, Mulder CJ, Lambrechts D, van Engeland M, Meijer GA. Comprehensive mutation analysis in colorectal flat adenomas. *PLoS One*. 2012;7(7):e41963. Epub 2012 Jul 27.
29. Wu Y, Grabsch H (joint first authors), Ivanova T, Tan IB, Murray J, Ooi CH, Wright AI, West NP, Hutchins GG, Wu J, Lee M, Lee J, Koo JH, Yeoh KG, van Grieken N, Ylstra B, Rha SY, Ajani J, Cheon JH, Noh SH, Lim KH, Boussioutas A, Lee JS, Tan P. Comprehensive genomic meta-analysis identified intra-tumoral stroma as a predictor of gastric cancer patient survival. *Gut*. 2013 Aug;62(8):1100-11.
30. Carvalho J, van Grieken NC, Pereira PM, Sousa S, Tijssen M, Buffart TE, Diosdado B, Grabsch H, Santos MA, Meijer G, Seruca R, Carvalho B, Oliveira C. Lack of microRNA-101 causes E-cadherin

- functional deregulation through EZH2 upregulation in intestinal gastric cancer. *J Pathol.* 2012 Sep;228(1):31-44
31. Voorham QJ, Carvalho B, Spiertz AJ, van Grieken NC, Mongera S, Rondagh EJ, van de Wiel MA, Jordanova ES, Ylstra B, Kliment M, Grabsch H, Rembacken BJ, Arai T, de Bruijne AP, Sanduleanu S, Quirke P, Mulder CJ, van Engeland M, Meijer GA. Chromosome 5q Loss in Colorectal Flat Adenomas. *Clin Cancer Res.* 2012 Sep 1;18(17):4560-4569
 32. Buffart TE, Carvalho B, van Grieken N, van Wieringen WN, Tijssen M, Meershoek-Klein Kranenbarg E, Verheul HMW, Grabsch H, Ylstra B, van de Velde CJH, Meijer GA. Losses of chromosome 5q and 14q are associated with favorable clinical outcome of patients with gastric cancer. *The Oncologist* 2012; 17(5):653-62
 33. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Lay-Keng Tan A, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. *Gut* 2012; 61:673-84
 34. Haan JC, Buffart TE, Eijk PP, van de Wiel MA, van Wieringen WN, Howdle PD, Mulder CJ, van de Velde CJ, Quirke P, Nagtegaal ID, van Grieken NC, Grabsch H, Meijer GA, Ylstra B. Small bowel adenocarcinoma copy number profiles are more closely related to colorectal than to gastric cancers. *Ann Oncol.* 2012 Feb;23(2):367-74.
 35. Mine S, Yamada K, Grabsch H, Sano T, Ishiyama A, Hirasawa T, Yamamoto N, Hiki N, Yamaguchi T. The prognostic significance of tumor laterality in patients with esophageal squamous cell carcinoma. *J Surg Oncol.* 2012 Jan;105(1):66-70
 36. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, Rha SY, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, Ajani JA, Lee JS, Tellez MS, Tan P. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. *Gastroenterology.* 2011 Aug;141(2):476-85, 485.e1-11.
 37. Brosens RP, Belt EJ, Haan JC, Buffart TE, Carvalho B, Grabsch H, Quirke P, Cuesta MA, Engel AF, Ylstra B, Meijer GA. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients. *Cell Oncol (Dordr).* 2011 Jun;34(3):215-23
 38. Buffart TE, Louw M, van Grieken NC, Tijssen M, Carvalho B, Ylstra B, Grabsch H, Mulder CJ, van de Velde CJ, van der Merwe SW, Meijer GA. Gastric cancers of Western European and African patients show different patterns of genomic instability. *BMC Med Genomics.* 2011 Jan 13;4(1):7.
 39. Zang ZJ, Ong CK, Cutcutache I, Yu W, Zhang SL, Huang D, Ler LD, Dykema K, Gan A, Tao J, Lim S, Liu Y, Futreal PA, Grabsch H, Furge KA, Goh LK, Rozen S, Teh BT, Tan P. Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. *Cancer Res.* 2011 Jan 1;71(1):29-39.
 40. Tweedle EM, Khattak I, Ang CW, Nedjadi T, Jenkins R, Park BK, Kalirai H, Dodson A, Azadeh B, Terlizzo M, Grabsch H, Mueller W, Myint S, Clark P, Wong H, Greenhalf W, Neoptolemos JP, Rooney PS, Costello E. Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. *Gut.* 2010 Nov;59(11):1501-10.
 41. Brosens RP, Haan JC, Carvalho B, Rustenburg F, Grabsch H, Quirke P, Engel AF, Cuesta MA, Maughan N, Flens M, Meijer GA, Ylstra B. Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. *J Pathol.* 2010 Apr 23;221(4):411-424.
 42. Takubo K, Fujita M, Izumiyama N, Nakamura K, Ishikawa N, Poon SS, Fujiwara M, Sawabe M, Matsuura M, Grabsch H, Arai T, Aida J. Q-FISH analysis of telomere and chromosome instability in the oesophagus with and without squamous cell carcinoma in situ. *J Pathol.* 2010 Jun;221(2):201-9.
 43. West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller W, Treanor D, Quirke P, Grabsch H. The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. *Br J Cancer.* 2010 May 11;102(10):1519-23.
 44. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. *Cell Oncol.* 2010;32(1-2):57-65.
 45. Diosdado B, Buffart TE, Watkins R, Carvalho B, Ylstra B, Tijssen M, Bolijn AS, Lewis F, Maude K, Verbeke C, Nagtegaal ID, Grabsch H, Mulder CJ, Quirke P, Howdle P, Meijer GA. High-resolution array comparative genomic hybridization in sporadic and celiac disease-related small bowel adenocarcinomas. *Clin Cancer Res.* 2010 Mar 1;16(5):1391-401.

46. Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y, Cheng LL, Lee J, Rha SY, Chung HC, Ganesan K, So J, Soo KC, Lim D, Chan WH, Wong WK, Bowtell D, Yeoh KG, Grabsch H, Boussioutas A, Tan P. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. *PLoS Genet*. 2009 Oct;5(10):e1000676.
47. Belien JA, Buffart TE, Gill AJ, Broeckaert MA, Quirke P, Meijer GA, Grabsch HI. Gross genomic damage measured by DNA image cytometry independently predicts gastric cancer patient survival. *Br J Cancer*. 2009 Sep 15;101(6):1011-8.
48. Buffart TE, van Grieken NC, Tijssen M, Coffa J, Ylstra B, Grabsch HI, van de Velde CJ, Carvalho B, Meijer GA. High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. *Virchows Arch*. 2009 Sep;455(3):213-23.
49. Parsons M, Grabsch H. How to make tissue microarrays. *Diagn Histopathology*. 2009 15:142-150.
50. Buffart TE, Overmeer RM, Steenbergen RD, Tijssen M, van Grieken NC, Snijders PJ, Grabsch HI, van de Velde CJ, Carvalho B, Meijer GA. MAL promoter hypermethylation as a novel prognostic marker in gastric cancer. *Br J Cancer*. 2008 Dec 2;99(11):1802-7.
51. Hou Q, Wu YH, Grabsch H, Zhu Y, Leong SH, Ganesan K, Cross D, Tan LK, Tao J, Gopalakrishnan V, Tang BL, Kon OL, Tan P. Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer. *Cancer Res*. 2008 Jun 15;68(12):4623-30.
52. Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH, Yu K, Rha SY, Chung HC, Ylstra B, Meijer G, Lian KO, Grabsch H, Tan P. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. *Cancer Res*. 2008 Jun 1;68(11):4277-86.
53. Buffart TE, Tijssen M, Krugers T, Carvalho B, Smeets SJ, Brakenhoff RH, Grabsch H, Meijer GA, Sadowski HB, Ylstra B. DNA quality assessment for array CGH by isothermal whole genome amplification. *Cell Oncol*. 2007;29(4):351-9.
54. Jong K., Marchiori E., van der Vaart A., Chin S.F., Carvalho B., Tijssen M., Eijk P.P., van den Ijssel P., Grabsch H., Quirke P., Oudejans J.J., Meijer G.A., Caldas C., Ylstra B. Cross-platform array comparative genomic hybridization meta-analysis separates hematopoietic and mesenchymal from epithelial tumors. *Oncogene*. 2007;26:1499-1506.
55. Carvalho B., Buffart T.E., Reis R.M., Mons T., Moutinho C., Silva P., van Grieken N.C.T, Grabsch H., van de Velde C.J.H., Ylstra B., Meijer G.A., Carneiro F. Mixed gastric carcinomas show similar chromosomal aberrations in both their diffuse and glandular components. *Cell Oncol*. 2006;28:283-294.
56. Jubb A.M., Chalasani S., Frantz G.D., Smits R., Grabsch H.I., Kavi V., Maughan N.J., Hillan K.J., Quirke P., Koeppen H. Achaete-scute like 2 (*ascl2*) is a target of Wnt signalling and is upregulated in intestinal neoplasia. *Oncogene*. 2006;25: 3445-3457.
57. Grabsch H., Dattani M., Barker L., Maughan N., Maude K., Hansen O., Gabbert H.E., Quirke P., Mueller W. Expression of DNA double strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer. *Clin Cancer Res*. 2006;12:1494-1500.
58. Hall P.A., Todd C.B., Hyland P.L., McDade S.S., Grabsch H., Dattani M., Hillan K.J. Russell S.E.H. The septin-binding protein anillin is overexpressed in diverse human tumors. *Clin Cancer Res*. 2005;11: 6780-6786.
59. Jubb A.M., Zhong F., Bheddah S., Grabsch H.I., Frantz G.D., Mueller W., Kavi V., Quirke P., Polakis P., Koeppen H. EphB2 is a prognostic factor in colorectal cancer. *Clin Cancer Res*. 2005;11:5181-5187.
60. Grabsch H., Lickvers K., Hansen O., Takeno S., Willers R., Stock W., Gabbert H.E., Mueller W. Prognostic value of cyclin B1 protein expression in colorectal cancer. *Am J Clin Pathol*. 2004;122:511-516.
61. Grabsch H., Kerr D., Quirke P. Is there a case for routine clinical application of ploidy measurement in gastrointestinal tumours? *Histopathology*. 2004;45:312-334.
62. Grabsch H., Askham J.M., Morrison E.E., Pomjanski N., Lickvers K., Parsons W.J., Boecking A., Gabbert H.E., Müller W. Expression of BUB1 protein in gastric cancer correlates with the histological subtype, but not with DNA ploidy or microsatellite instability. *J Pathol*. 2004; 202:208-214.
63. Grabsch H., Takeno S., Parsons W.J., Pomjanski N., Boecking A., Gabbert H.E., Müller W. Overexpression of mitotic checkpoint genes *BUB1*, *BUBR1* and *BUB3* in gastric cancer - association with tumour cell proliferation. *J Pathol* 2003;200:16-22.
64. Krieg A., Mahotka C., Krieg T., Grabsch H., Müller W., Takeno S., Suschek C.V., Heydthausen M., Gabbert H.E., Gerharz C.D. Expression of different survivin variants in gastric carcinomas: First clues to a role of survivin-2B in tumour progression. *Br J Cancer*. 2002; 86:737-743.

65. **Grabsch H.**, Takeno S., Noguchi T., Hommel G., Gabbert H.E., Müller W. Different patterns of β -catenin expression in gastric carcinomas - relationship with clinico-pathological parameters and prognostic outcome. *Histopathology*. 2001;39: 141-149.
66. Müller W., **Grabsch H.**, Takeno S., Noguchi T., Hommel G., Gabbert H.E. Prognostic value of the cyclin-dependent kinase inhibitor p27/kip1 in gastric cancer. *Anticancer Res*. 2000;20:1787-92.
67. Weiergräber M., Pereverzev A., Vajna R., Henry M., Schramm M., Nastainczyk W., **Grabsch H.**, Schneider T. Immunodetection of α 1E voltage-gated Ca^{2+} channel in chromogranin-positive muscle cells of rat heart, and in distal tubules of human kidney. *J Histochem Cytochem*. 2000; 48:807-820.
68. **Grabsch H.**, Pereverzev A., Weiergräber M., Schramm M., Henry M., Vajna R., Beattie R.E., Volsen S.G. Klöckner U., Hescheler J., Schneider T. Immunohisto-chemical detection of α 1E voltage-gated Ca^{2+} channel isoforms in cerebellum, INS-1 cells, and neuroendocrine cells of the digestive system. *J Histochem Cytochem*. 1999; 47:981-993.
69. Vajna R., Schramm M., Pereverzev A., Arnhold S., **Grabsch H.**, Klöckner U., Perez-Reyes E., Hescheler J., Schneider T. New isoforms of the neuronal Ca^{2+} channel α 1E subunit in islets of Langerhans and kidney. Distribution of voltage-gated Ca^{2+} channels α 1 subunits in cell lines and tissues. *Eur J Biochem*. 1998; 257:274-285.
70. Pereverzev A., Klöckner U., Henry M., **Grabsch H.**, Vajna R., Olyschläger S., Viatchenko-Karpinski S., Schröder R., Hescheler J., Schneider T. Structural diversity of voltage-dependent Ca^{2+} channel α 1E-subunit. *Eur J Neurosci*. 1998; 10: 916-925.
71. Angelov D.N., Arnhold S., Andressen C., **Grabsch H.**, Puschmann M., Hescheler J., Addicks K. Temporospacial relationships between macroglia and microglia during in vitro differentiation of murine stem cells. *Dev Neurosci*. 1998; 20:42-51.
72. Mehrke G., Pereverzev A., **Grabsch H.**, Hescheler J., Schneider T. Receptor mediated modulation of recombinant neuronal class E calcium channels. *FEBS Lett*. 1997; 408: 261-270.

Book Chapters

Mueller W and Grabsch H

Role of Immunohistochemical Expression of BUB1 Protein in Gastric Cancer

Chapter 8 in *Handbook of Immunohistochemistry and in situ Hybridization of Human Carcinomas. Volume 4: Molecular Genetics, Gastrointestinal Carcinoma, and Ovarian Carcinoma*, edited by M. Hayat, Elsevier (2006)

Grabsch HI

Pathology of oesophageal and gastric tumours

Chapter 1 in *Oesophagogastric surgery, 5th edition*. Editors: S Michael Griffin, Simon A Raimes, John Shenfine. Elsevier (2013)

Grabsch HI

Alimentary system

Chapter 15 in *General and systematic pathology, 5th edition*. Editor: Simon S Cross. Elsevier (2013)

Carcneiro F and Grabsch HI

Pathogenesis of Gastric Cancer

Chapter 6 in *Minimally Invasive Foregut Surgery for Malignancy: Principles and Practice*. Editor: Steven N Hochwald. Springer 2015